370 filings
Page 7 of 19
8-K
38in5
11 Dec 18
Cellectar Granted Japanese Patent for CLR 131
4:01pm
8-K
zz9ey3o06 o3m1xg
4 Dec 18
Regulation FD Disclosure
4:01pm
8-K
ql0 e9anfqg4ckntqyoy
16 Nov 18
Departure of Directors or Certain Officers
4:02pm
8-K
o68 90os1bmv
13 Nov 18
Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update
8:45am
8-K
uh2vr5ed3bn6le
13 Nov 18
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies
6:04am
8-K
2qih4t7re6xp1
3 Oct 18
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
12:00am
8-K
lfxecn mme
2 Oct 18
Regulation FD Disclosure
9:22am
8-K
w5b3vs5zmcwlh 17i
25 Sep 18
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
4:01pm
8-K
h60q9b ld85gi
24 Sep 18
Cellectar Biosciences Provides an Update on the FDA Import Alert
4:05pm
8-K
r35ktkktr2dk3
17 Sep 18
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
12:00am
8-K
71ym6277ai 71
6 Sep 18
Regulation FD Disclosure
12:00am
8-K
b6z4jqjof5 9sv46
20 Aug 18
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
12:00am
8-K
vclqg1u5xe
13 Aug 18
Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma
4:01pm
8-K
7efm5yta3fk23t56
10 Aug 18
Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update
8:15am
8-K
35nxpp1ekuq nx5
1 Aug 18
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
4:14pm
8-K
nfei9
31 Jul 18
Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
4:53pm
8-K
vigrz6mcr8dsncvw
27 Jul 18
Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering
8:45am
8-K
eps2g6q
18 Jul 18
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
4:17pm
8-K
9sh2k c7s8giy
17 Jul 18
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study
4:05pm
8-K
yq09pmw4ygtvltz9x
13 Jul 18
Cellectar Announces 1-for-10 Reverse Stock Split
4:15pm